Catalog No.
DVV03609
Expression system
Mammalian Cells
Species reactivity
Zaire ebolavirus (strain Mayinga-76) (ZEBOV) (Zaire Ebola virus)
Host species
Human
Isotype
IgG
Clonality
Monoclonal
Target
Envelope glycoprotein, GP1,2, GP, Shed GP, GP1,2-delta, GP1, GP2, GP
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q05320
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Zmapp
Clone ID
Zmapp
Impact of most promising Ebola therapies on survival: a secondary analysis during the tenth outbreak in the Democratic Republic of Congo., PMID:40375337
Ophthalmological manifestations and plasma markers of inflammation in Ebola survivors in post-treatment era., PMID:40301432
Remdesivir, mAb114, REGN-EB3, and ZMapp partially rescue nonhuman primates infected with a low passage Kikwit variant of Ebola virus., PMID:40268932
Drug repositioning as a promising approach for the eradication of emerging and re-emerging viral agents., PMID:40100484
ZMapp reduces diffusion of Ebola viral particles in fresh human cervicovaginal mucus., PMID:38713593
Ebola-specific therapeutic antibodies from lab to clinic: The example of ZMapp., PMID:38580170
Green Biologics: Harnessing the Power of Plants to Produce Pharmaceuticals., PMID:38139405
Effect of anti-Ebola virus monoclonal antibodies on endogenous antibody production in survivors of Ebola virus disease in the Democratic Republic of the Congo: an observational cohort study., PMID:38043556
A high-throughput single-particle imaging platform for antibody characterization and a novel competition assay for therapeutic antibodies., PMID:36609657
Effects of therapies for Ebola virus disease: a systematic review and network meta-analysis., PMID:35803293
A systematic review of Ebola virus disease outbreaks and an analysis of the efficacy and safety of newer drugs approved for the treatment of Ebola virus disease by the US Food and Drug Administration from 2016 to 2020., PMID:35085865
Reproducibility and flexibility of monoclonal antibody production with Nicotiana benthamiana., PMID:35000569
Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines., PMID:34579229
Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection., PMID:34526994
Plant-based vaccine research development against viral diseases with emphasis on Ebola virus disease: A review study., PMID:34481336
Atoltivimab/maftivimab/odesivimab (Inmazeb) combination to treat infection caused by Zaire ebolavirus., PMID:34405205
Commentary title: COVID-19 research, Africa, and global health., PMID:33558836
Clinical aspects of Ebola virus disease: a review., PMID:32487785
Ebola., PMID:32441897
Recurrent Ebolavirus disease in the Democratic Republic of Congo: update and challenges., PMID:31909070
A meta-analysis of clinical studies conducted during the West Africa Ebola virus disease outbreak confirms the need for randomized control groups., PMID:31776287
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics., PMID:31774950
New antibodies best ZMapp in Ebola trial., PMID:31578509
Therapeutic strategies to target the Ebola virus life cycle., PMID:31341272
Characterisation of infectious Ebola virus from the ongoing outbreak to guide response activities in the Democratic Republic of the Congo: a phylogenetic and in vitro analysis., PMID:31300330
Anti-Ebola therapy for patients with Ebola virus disease: a systematic review., PMID:31046707
2018 Ebola virus disease outbreak in Équateur Province, Democratic Republic of the Congo: a retrospective genomic characterisation., PMID:31000465
Medical countermeasures during the 2018 Ebola virus disease outbreak in the North Kivu and Ituri Provinces of the Democratic Republic of the Congo: a rapid genomic assessment., PMID:31000464
Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection., PMID:30728263
Public health round-up., PMID:30618458
Randomised controlled trial begins for Ebola therapeutics., PMID:30527603
Role of the Ebola membrane in the protection conferred by the three-mAb cocktail MIL77., PMID:30514891
Human Polyclonal Antibodies Produced by Transchromosomal Cattle Provide Partial Protection Against Lethal Zaire Ebolavirus Challenge in Rhesus Macaques., PMID:30053153
Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms., PMID:29939318
Experimental drugs poised for use in Ebola outbreak., PMID:29789732
Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region., PMID:29736037
ZMapp Reinforces the Airway Mucosal Barrier Against Ebola Virus., PMID:29688496
Safeguarding against Ebola: Vaccines and therapeutics to be stockpiled for future outbreaks., PMID:29621257
The B cell death function of obinutuzumab-HDEL produced in plant (Nicotiana benthamiana L.) is equivalent to obinutuzumab produced in CHO cells., PMID:29324849
Nubia's mother: being pregnant in the time of experimental vaccines and therapeutics for Ebola., PMID:29297408
Gene Transfer of ZMapp Antibodies Mediated by Recombinant Adeno-Associated Virus Protects Against Ebola Infections., PMID:29179602
[Integrating clinical research into epidemic response: the field perspective in the Ebola experience]., PMID:28994386
Discovering Drugs for the Treatment of Ebola Virus., PMID:28890666
Production of Functional Anti-Ebola Antibodies in Pichia pastoris., PMID:28786662
Transient Production of Recombinant Pharmaceutical Proteins in Plants: Evolution and Perspectives., PMID:28721831
The ongoing evolution of antibody-based treatments for Ebola virus infection., PMID:28357917
Trial of ZMapp for Ebola Virus Infection., PMID:28207206
Trial of ZMapp for Ebola Virus Infection., PMID:28199801
Chemically Modified Human Serum Albumin Potently Blocks Entry of Ebola Pseudoviruses and Viruslike Particles., PMID:28167539
First Newborn Baby to Receive Experimental Therapies Survives Ebola Virus Disease., PMID:28073857
For research use only. Not for human or drug use.
